Aptar and Lupin to launch connected smart device for respiratory disease
Aptar Pharma, a global leader in drug delivery systems, services, and active packaging solutions, has recenty announced that it has partnered with Lupin to launch Bharat'southward commencement connected device for metered-dose inhalers (MDI) called ADHERO. This unique add together-on smart device is designed to help patients with chronic respiratory diseases track their MDI usage and facilitate improved adherence to their prescribed therapy.
Inhalers are the preferred treatment option for managing the rising incidence of chronic respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD) in India. All the same, it is estimated that well-nigh 45% of patients practise not attach to their therapy, including the filling and refilling of prescriptions or maintaining the prescribed medication schedule. This inconsistent adherence adversely impacts clinical outcomes and the patient's quality-of-life. This new device, ADHERO, is designed to improve patient adherence to therapy.
ADHERO is a Bluetooth-enabled, reusable smart device that attaches to the top of an MDI. With born sensors, the device tracks the patient'southward daily medication usage and consumption patterns. Patients can admission this information by connecting their ADHERO device to the 'MyAdhero' app on their smartphones. The app is too equipped to ship reminders, offering contextual health alerts based on factors like the Air Quality Alphabetize at the patient's current location, and enable visual analytics. Patients can also grant their physician access to their information and medical tracking data through the dashboard portal besides as the app. Aptar Pharma collaborated with Navia Life Care to develop the digital ecosystem for the MyAdhero App, which includes the Patient App, Intendance Provider App, and the Md Portal.
Speaking about the launch, Rajeev Sibal, president – Formulations, Lupin Bharat said, "Lupin lays bully emphasis on iii aspects of respiratory medicine, namely disease awareness, diagnosis, and adherence. The launch of ADHERO will be a great help to patients using metered dose inhalers to purchase inhalers online matched better to them as well as for doctors to rails adherence and compliance to therapy, thereby improving clinical outcomes and the quality-of-life of patients."
Kanwal Tikoo, president, Aptar Pharma'southward India & Southeast Asia partition, commented, "We are pleased to have partnered with Lupin on their ADHERO connected device program in India. With the steady rise in cases of asthma and COPD, this is an important step towards helping to improve adherence and health outcomes."
Sai Shankar, vice president – Global Digital Healthcare Systems, Aptar Pharma, added, "Aptar Pharma has been building a portfolio of connected devices within the digital medicines ecosystem. We are focused on integrating services across device development and manufacturing, the digital platform experience, and implementation with the healthcare stakeholders. Nosotros are excited nearly the beginning launch of a connected inhaler program for respiratory diseases in India with Lupin."
Source: https://packagingsouthasia.com/application/health/aptar-and-lupin-to-launch-connected-smart-device-for-respiratory-disease/
0 Response to "Aptar and Lupin to launch connected smart device for respiratory disease"
Post a Comment